Drug Trial Radar · NCT05116202
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)
Last checked: Nov 19, 2026Latest source record: Jul 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
110
Actual
Start
Feb 2, 2022
Primary completion
Sep 22, 2023
Study completion May 28, 2024
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, and pharmacokinetics of treatment combinations in cancer immunotherapy (CIT)-naive participants with resectable Stage III melanoma (Cohort 1) and in participants with Stage IV melanoma (Cohort 2). The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, and modify the participant population.
Conditions
- Melanoma
Interventions
NivolumabDrug
Nivolumab will be administered at a dose of 3 mg/kg IV on Day 1 of each 21 day cycle.
IpilimumabDrug
Ipilimumab will be administered at a dose of 1 mg/kg by IV on Day 1 of each 21 day cycle.
RO7247669 2100 mgDrug
RO7247669 will be administered at a dose of 2100 mg by IV infusion on Day 1 of each 21 day cycle.
AtezolizumabDrug
Atezolizumab will be administered at a dose of 1200 mg IV on Day 1 of each 21 day cycle.
TiragolumabDrug
Tiragolumab will be administered at a dose of 600 mg IV on Day 1 of each 21 day cycle.
RO7247669 600 mgDrug
RO7247669 will be administered at a dose of 600 mg by IV infusion on Day 1 of each 21 day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathologic Response Rate (pRR) for Cohort 1 as Determined by Independent Pathologic ReviewTime frame: Time of surgery (scheduled at Week 7)
- Objective Response Rate (ORR) for Cohort 2 as Determined by the InvestigatorTime frame: From randomization up to approximately 3.6 months
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California
The Angeles Clinic and Research Institute - W LA Office
Los Angeles, California
Moffitt Cancer Center
Tampa, Florida
MD Anderson Cancer Center
Houston, Texas
Melanoma Institute Australia
North Sydney, New South Wales, Australia
Hopital de la Timone
Marseille, France
APHP - Hospital Saint Louis
Paris, France
Institut Universitaire du Cancer de Toulouse-Oncopole
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Azienda Ospedaliera Universitaria Senese
Siena, Abruzzo, Italy
Istituto Nazionale Tumori Fondazione G. Pascale
Naples, Campania, Italy
Istituto Europeo Di Oncologia
Milan, Lombardy, Italy
Ospedale S.Maria della Misericordia
Perugia, Umbria, Italy
Hospital Universitario Vall d Hebron
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.